Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity
Status:
Completed
Trial end date:
2018-10-18
Target enrollment:
Participant gender:
Summary
Patients with spondyloarthritis, already treated by TNF blocker (adalimumab, etanercept or
infliximab), and in stable low disease activity for at least 6 months, will be randomized
into 2 groups: either keeping on their usual treatment with stable doses or progressive
spacing of injections of their treatment. Follow-up will be done every 3 months during 12
months, with regular monitoring of disease activity and, in patients from the group
"spacing", modification of the rhythm of injections according to health state and predefined
protocol.